Article Information
- Received September 9, 2006
- Accepted February 22, 2007
- First published April 4, 2007.
- Version of record published April 4, 2007.
Author Information
- Zdenek Berger1,
- Hanno Roder1,
- Amanda Hanna1,
- Aaron Carlson1,
- Vijayaraghavan Rangachari1,
- Mei Yue1,
- Zbigniew Wszolek1,
- Karen Ashe2,
- Joshua Knight1,
- Dennis Dickson1,
- Cathy Andorfer1,
- Terrone L. Rosenberry1,
- Jada Lewis1,
- Mike Hutton1, and
- Christopher Janus1
- 1Mayo Clinic Jacksonville, Jacksonville, Florida 32224, and
- 2Department of Neurology, University of Minnesota Medical School, Minneapolis, Minnesota 55455
- Correspondence should be addressed to Mike Hutton, Mayo Clinic Jacksonville, 4500 San Pablo Road, Birdsall Building, Jacksonville, FL 32224. hutton.michael{at}mayo.edu
Author contributions
Disclosures
- Received September 9, 2006.
- Accepted February 22, 2007.
-
This work was supported by an EMBO long-term fellowship (Z.B.), National Institutes of Health Grants P01-AG017216 (M.H.), R01-NS4635 (J.L.), and P01-AG014449 and P30 AG10161 (D.D.), John Douglas French Alzheimer's Foundation (C.A.), Alzheimer's Disease Research Center Pilot Project and American Federation for Aging Research grants (C.J.), and Morris K. Udall Parkinson's Disease Research Center of Excellence Grant P50-NS40256-06 (Z.W., D.D.). We are grateful to Dr. S. H. Yen for helpful discussion, Dr. Peter Davies for providing CP13 and PHF1 tau antibodies, and Dr. Lester Binder for tau12 and TauC3 antibodies. We are grateful to Judith Wilson for technical assistance, Zeshan Ahmed and John Gonzalez for help with samples from human tauopathies, and Dr. Jason Eriksen, Dr. Cynthia Zehr, and Linda Rousseau for assistance with imaging and NFT counts.
- Correspondence should be addressed to Mike Hutton, Mayo Clinic Jacksonville, 4500 San Pablo Road, Birdsall Building, Jacksonville, FL 32224. hutton.michael{at}mayo.edu
Online Impact